HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TUBB1
tubulin beta 1 class VI
Chromosome 20 · 20q13.32
NCBI Gene: 81027Ensembl: ENSG00000101162.4HGNC: HGNC:16257UniProt: Q9H4B7
88PubMed Papers
21Diseases
87Drugs
17Pathogenic Variants
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
ciliummicrotubule cytoskeletonintercellular bridgeextracellular exosomeautosomal dominant macrothrombocytopeniahemorrhagic diseasebreast cancernon-small cell lung carcinoma
✦AI Summary

TUBB1 encodes β1-tubulin, a major structural component of microtubules that form heterodimers with α-tubulin 1. These microtubules are fundamental cytoskeletal elements organized through GTP-dependent polymerization, with β1-tubulin playing specialized roles in proplatelet formation and platelet shape maintenance through incorporation into the microtubular marginal ring 1. TUBB1 is also expressed in developing thyroid tissue and participates in thyroid migration and hormone secretion 2. Pathogenic TUBB1 variants cause macrothrombocytopenia (isolated, autosomal dominant) with incomplete penetrance and variable phenotypic expression dependent on allelic burden 1. Mutations produce non-functional α/β-tubulin dimers that cannot incorporate into microtubules, impairing proplatelet formation and resulting in reduced platelet counts with increased platelet size 21. TUBB1 variants also cause thyroid dysgenesis leading to congenital hypothyroidism through impaired thyroid development and hormone secretion 23. Additionally, TUBB1 dysfunction disrupts DNA damage responses and diminishes apoptosis, conferring genome instability and increased leukemogenesis risk in inherited thrombocytopenia 4. Elevated TUBB1 expression correlates with favorable prognosis in osteosarcoma and associates with protective effects against osteoarthritis 56. These diverse functions reflect TUBB1's critical structural role across multiple tissues.

Sources cited
1
β1-tubulin role in proplatelet formation, platelet shape maintenance through marginal ring incorporation, and incomplete penetrance of pathogenic variants
PMID: 34516618
2
TUBB1 mutations cause non-functional dimers, thyroid dysgenesis, and abnormal platelet physiology including macroplatelet formation
PMID: 30446499
3
TUBB1 variants associated with thyroid dysgenesis in congenital hypothyroidism, functional effects on gene expression and cell proliferation
PMID: 40071799
4
TUBB1 dysfunction impairs microtubule assembly, attenuates DNA damage response, diminishes apoptosis, and causes genome instability
PMID: 30854628
5
TUBB1 elevated expression associates with favorable prognosis in osteosarcoma and correlates with immune cell infiltration
PMID: 35388751
6
Increased TUBB1 expression reduces osteoarthritis risk through Mendelian randomization analysis
PMID: 41291434
7
TUBB1 mutations linked to neurodevelopmental defects as part of tubulinopathies affecting brain development
PMID: 36943622
Disease Associationsⓘ21
autosomal dominant macrothrombocytopeniaOpen Targets
0.74Strong
hemorrhagic diseaseOpen Targets
0.61Moderate
breast cancerOpen Targets
0.61Moderate
non-small cell lung carcinomaOpen Targets
0.61Moderate
breast neoplasmOpen Targets
0.60Moderate
neoplasmOpen Targets
0.60Moderate
breast carcinomaOpen Targets
0.60Moderate
goutOpen Targets
0.59Moderate
Hodgkins lymphomaOpen Targets
0.58Moderate
multiple myelomaOpen Targets
0.58Moderate
familial Mediterranean feverOpen Targets
0.58Moderate
cervical cancerOpen Targets
0.58Moderate
prostate cancerOpen Targets
0.58Moderate
diffuse large B-cell lymphomaOpen Targets
0.58Moderate
head and neck malignant neoplasiaOpen Targets
0.57Moderate
lymphomaOpen Targets
0.57Moderate
stomach neoplasmOpen Targets
0.57Moderate
prostate neoplasmOpen Targets
0.56Moderate
adenocarcinomaOpen Targets
0.56Moderate
head and neck neoplasiaOpen Targets
0.56Moderate
Macrothrombocytopenia, isolated, 1, autosomal dominantUniProt
Pathogenic Variants17
NM_030773.4(TUBB1):c.779T>C (p.Phe260Ser)Pathogenic
not provided|Macrothrombocytopenia, isolated, 1, autosomal dominant|TUBB1-related disorder
★★☆☆2026→ Residue 260
NM_030773.4(TUBB1):c.62G>A (p.Trp21Ter)Likely pathogenic
not provided
★☆☆☆2025→ Residue 21
NM_030773.4(TUBB1):c.796_798del (p.Phe266del)Likely pathogenic
Macrothrombocytopenia, isolated, 1, autosomal dominant
★☆☆☆2024→ Residue 266
NM_030773.4(TUBB1):c.79G>T (p.Glu27Ter)Likely pathogenic
not provided
★☆☆☆2024→ Residue 27
NM_030773.4(TUBB1):c.128_131delinsCCC (p.Gln43fs)Likely pathogenic
Macrothrombocytopenia, isolated, 1, autosomal dominant
★☆☆☆2024→ Residue 43
NM_030773.4(TUBB1):c.579dup (p.Glu194Ter)Likely pathogenic
not provided
★☆☆☆2024→ Residue 194
NM_030773.4(TUBB1):c.838C>T (p.Gln280Ter)Likely pathogenic
not provided
★☆☆☆2024→ Residue 280
NM_030773.4(TUBB1):c.166+1G>CLikely pathogenic
Macrothrombocytopenia, isolated, 1, autosomal dominant
★☆☆☆2022
NM_030773.4(TUBB1):c.57+1G>ALikely pathogenic
Macrothrombocytopenia, isolated, 1, autosomal dominant
★☆☆☆2020
NM_030773.4(TUBB1):c.624T>A (p.Tyr208Ter)Pathogenic
Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss
★☆☆☆2019→ Residue 208
NM_030773.4(TUBB1):c.945C>A (p.Cys315Ter)Likely pathogenic
Thrombocytopenia
★☆☆☆2019→ Residue 315
NM_030773.4(TUBB1):c.1194del (p.Trp397_Tyr398insTer)Likely pathogenic
Macrothrombocytopenia
★☆☆☆2019→ Residue 397
NM_030773.4(TUBB1):c.806G>A (p.Gly269Asp)Pathogenic
Macrothrombocytopenia, isolated, 1, autosomal dominant
★☆☆☆→ Residue 269
NM_030773.4(TUBB1):c.1257_1260delinsTGAGTACCATGTT (p.Ser420delinsGluTyrHisVal)Likely pathogenic
TUBB1-related disorder
☆☆☆☆2024→ Residue 420
NM_030773.4(TUBB1):c.318C>G (p.Tyr106Ter)Pathogenic
Congenital hypothyroidism
☆☆☆☆2016→ Residue 106
NM_030773.4(TUBB1):c.726C>G (p.Phe242Leu)Likely pathogenic
Macrothrombocytopenia, isolated, 1, autosomal dominant
☆☆☆☆→ Residue 242
NM_030773.4(TUBB1):c.297C>A (p.Asn99Lys)Likely pathogenic
Macrothrombocytopenia
☆☆☆☆→ Residue 99
View on ClinVar ↗
Drug Targets87
ABT-751Phase II
Tubulin beta inhibitor
AGS-16C3FPhase II
Tubulin disrupting agent
renal cell carcinoma
ANETUMAB RAVTANSINEPhase II
Tubulin inhibitor
malignant pleural mesothelioma
ANG1005Phase II
Tubulin inhibitor
ANVATABART OPADOTINPhase II/III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
APRUTUMAB IXADOTINPhase I
Fibroblast growth factor receptor 2 binding agent
cancer
ASG-5MEPhase I
Choline transporter-like protein 4 binding agent
Malignant Pancreatic Neoplasm
AVE-9633Phase I
Myeloid cell surface antigen CD33 binding agent
myeloid leukemia
AZINTUXIZUMAB VEDOTINPhase I
SLAM family member 7 binding agent
multiple myeloma
BELANTAMAB MAFODOTINApproved
Tumor necrosis factor receptor superfamily member 17 binding agent
multiple myeloma
BIIB-015Phase I
Teratocarcinoma-derived growth factor 1 binding agent
BIVATUZUMAB MERTANSINEUNKNOWN
Tubulin inhibitor
BMS-275183Phase II
Tubulin stabiliser
BRENTUXIMAB VEDOTINApproved
Tubulin inhibitor
CABAZITAXELApproved
Tubulin inhibitor
prostate cancer
CANTUZUMAB MERTANSINEPhase II
Tubulin inhibitor
non-small cell lung carcinoma
CANTUZUMAB RAVTANSINEPhase II
Mucin-1 binding agent
stomach neoplasm
COLCHICINEApproved
Tubulin inhibitor
familial Mediterranean fever
COLTUXIMAB RAVTANSINEPhase II
Tubulin inhibitor
diffuse large B-cell lymphoma
CROLIBULINPhase I/II
Tubulin inhibitor
DAVUNETIDEPhase III
Tubulin stabiliser
Cognitive impairment
DENINTUZUMAB MAFODOTINPhase II
B-lymphocyte antigen CD19 binding agent
diffuse large B-cell lymphoma
DEPATUXIZUMAB MAFODOTINPhase III
Epidermal growth factor receptor erbB1 binding agent
glioblastoma multiforme
DISITAMAB VEDOTINPhase III
Receptor tyrosine-protein kinase erbB-2 binding agent
breast cancer
DOCETAXELApproved
Tubulin inhibitor
DOCETAXEL ANHYDROUSApproved
Tubulin stabiliser
prostate cancer
DOLASTATIN-10Phase II
Tubulin inhibitor
ENAPOTAMAB VEDOTINPhase I/II
Tyrosine-protein kinase receptor UFO binding agent
ENFORTUMAB VEDOTINApproved
Nectin-4 binding agent
EPOTHILONE DPhase II
Tubulin stabiliser
breast cancer
ERIBULINApproved
Tubulin inhibitor
breast cancer
ERIBULIN MESYLATEApproved
Tubulin inhibitor
breast cancer
FOSBRETABULINPhase III
Tubulin disrupting agent
thyroid cancer
FOSBRETABULIN DISODIUMPhase II
Tubulin inhibitor
neuroendocrine carcinoma
FOSBRETABULIN TROMETHAMINEPhase II/III
Tubulin disrupting agent
ovarian cancer
GLEMBATUMUMAB VEDOTINApproved
Transmembrane glycoprotein NMB binding agent
lymphoma
IMGN-388Phase I
Vitronectin receptor alpha binding agent
INDATUXIMAB RAVTANSINEPhase II
Syndecan-1 binding agent
multiple myeloma
INDIBULINPhase II
Tubulin inhibitor
INDUSATUMAB VEDOTINPhase II
Heat-stable enterotoxin receptor binding agent
IXABEPILONEApproved
Tubulin inhibitor
breast cancer
KOS-1584Phase II
Tubulin stabiliser
non-small cell lung carcinoma
LADIRATUZUMAB VEDOTINPhase II
Zinc transporter ZIP6 binding agent
breast cancer
LAROTAXELPhase III
Tubulin stabiliser
urinary bladder carcinoma
LEXIBULINPhase II
Tubulin inhibitor
glioblastoma multiforme
LIFASTUZUMAB VEDOTINPhase II
Sodium-dependent phosphate transport protein 2B binding agent
ovarian cancer
LORVOTUZUMAB MERTANSINEPhase II
Neural cell adhesion molecule 1 binding agent
MECBOTAMAB VEDOTINPhase II
Tyrosine-protein kinase receptor UFO binding agent
ovarian cancer
MILATAXELPhase II
Tubulin inhibitor
MIRVETUXIMAB SORAVTANSINEApproved
Folate receptor alpha binding agent
ovarian cancer
MLN-2704Phase I/II
Glutamate carboxypeptidase II binding agent
prostate cancer
OMBRABULINPhase III
Tubulin inhibitor
sarcoma
PACLITAXELApproved
Tubulin inhibitor
PACLITAXEL DOCOSAHEXAENOIC ACIDPhase III
Tubulin stabiliser
non-small cell lung carcinoma
PACLITAXEL POLIGLUMEXApproved
Tubulin stabiliser
neoplasm
PATUPILONEPhase III
Tubulin stabiliser
PF-06263507Phase I
Tubulin inhibitor
PINATUZUMAB VEDOTINPhase II
CD22 binding agent
diffuse large B-cell lymphoma
PLINABULINPhase III
Tubulin inhibitor
non-small cell lung carcinoma
PLOCABULINPhase II
Tubulin inhibitor
colorectal cancer
POLATUZUMAB VEDOTINApproved
Tubulin inhibitor
diffuse large B-cell lymphoma
PRALUZATAMAB RAVTANSINEPhase II
Tubulin inhibitor
neoplasm
RG-7598Phase I
Fc receptor-like protein 5 binding agent
multiple myeloma
RG-7600Phase I
Tubulin inhibitor
ovarian cancer
RG-7636Phase I
Tubulin inhibitor
melanoma
RG-7841Phase I
Lymphocyte antigen 6E binding agent
SAGOPILONEPhase II
Tubulin stabiliser
breast cancer
SAR-566658Phase II
Tubulin inhibitor
triple-negative breast cancer
SOBLIDOTINPhase II
Tubulin inhibitor
SOFITUZUMAB VEDOTINPhase I
Mucin-16 binding agent
fallopian tube cancer
T-900607Phase II
Tubulin disrupting agent
hepatocellular carcinoma
TELISOTUZUMAB VEDOTINPhase III
Hepatocyte growth factor receptor binding agent
non-small cell lung carcinoma
TISOTUMAB VEDOTINApproved
Coagulation factor III binding agent
cervical cancer
TRASTUZUMAB BOTIDOTINPhase III
Tubulin inhibitor
HER2 Positive Breast Carcinoma
TRASTUZUMAB EMTANSINEApproved
Receptor protein-tyrosine kinase erbB-2 binding agent
TUSAMITAMAB RAVTANSINEPhase III
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
non-small cell lung carcinoma
VANDORTUZUMAB VEDOTINPhase I
Metalloreductase STEAP1 binding agent
prostate cancer
VERUBULINPhase II
Tubulin disrupting agent
VINBLASTINEApproved
Tubulin inhibitor
VINBLASTINE SULFATEApproved
Tubulin inhibitor
lymphoma
VINCRISTINEApproved
Tubulin inhibitor
VINCRISTINE SULFATEApproved
Tubulin inhibitor
VINFLUNINEApproved
Tubulin inhibitor
VINFLUNINE DITARTRATEApproved
Tubulin inhibitor
benign urinary system neoplasm
VINORELBINEApproved
Tubulin inhibitor
VINORELBINE TARTRATEApproved
Tubulin inhibitor
VORSETUZUMAB MAFODOTINPhase I
Tubulin inhibitor
renal cell carcinoma
Related Genes
TUBA1BProtein interaction98%TUBA1CProtein interaction96%TUBA8Protein interaction96%TUBA1AProtein interaction96%GJA1Protein interaction93%MAPTProtein interaction92%
Tissue Expression6 tissues
Bone Marrow
100%
Lung
44%
Liver
6%
Heart
3%
Brain
2%
Ovary
2%
Gene Interaction Network
Click a node to explore
TUBB1TUBA1BTUBA1CTUBA8TUBA1AGJA1MAPT
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q9H4B7
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
1.59LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF1.18 [0.89–1.59]
RankingsWhere TUBB1 stands among ~20K protein-coding genes
  • #5,450of 20,598
    Most Researched88
  • #67of 1,025
    FDA-Approved Drug Targets25 · top 10%
  • #2,339of 5,498
    Most Pathogenic Variants17
  • #15,609of 17,882
    Most Constrained (LOEUF)1.59
Genes detectedTUBB1
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants.
PMID: 37647632
Blood · 2023
1.00
2
TUBB1 variants and human platelet traits.
PMID: 29333906
Platelets · 2018
0.90
3
Expanding the genetic spectrum of TUBB1-related thrombocytopenia.
PMID: 34516618
Blood Adv · 2021
0.80
4
ADAM19 and TUBB1 Correlate with Tumor Infiltrating Immune Cells and Predicts Prognosis in Osteosarcoma.
PMID: 35388751
Comb Chem High Throughput Screen · 2023
0.70
5
Genetic and functional analysis of TUBB1 variants in congenital hypothyroidism.
PMID: 40071799
Endokrynol Pol · 2025
0.60